ImmunityBio, Inc. (NASDAQ: IBRX) Announces Results of 2026 Annual Meeting of Stockholders
ImmunityBio, Inc. (Nasdaq: IBRX) has released the official results of its 2026 Annual Meeting of Stockholders, which was held on June 9, 2026. The meeting featured proposals that are central to the company’s governance and financial oversight, with direct implications for its leadership continuity and external audit oversight.
Key Points from the Report
- Annual Meeting Date: June 9, 2026
- Record Date: April 13, 2026
- Total Shares Outstanding: 1,047,345,861
- Shares Represented at the Meeting: 885,167,059 (approx. 85% of outstanding shares)
- Quorum Achieved: Yes
Major Voting Outcomes
1. Election of Directors
Shareholders voted to re-elect all nine members of the Board of Directors for a one-year term expiring at the 2027 Annual Meeting. The directors’ continued tenure provides stability and signals investor confidence in current leadership. The directors’ terms will continue until their successors are duly elected and qualified or until their earlier retirement, resignation, disqualification, removal, or death.
- Notable Board Members:
- Patrick Soon-Shiong, M.D. (Executive Chairman & CEO)
- Christobel Selecky
Detailed Voting Results:
- Patrick Soon-Shiong, M.D.: 714,631,732 votes in favor; 15,669,861 withheld; 151,521,174 broker non-votes
- Christobel Selecky: 722,387,537 votes in favor; 11,258,348 withheld; 151,521,174 broker non-votes
- Other Directors: All received similar overwhelming support
2. Ratification of Deloitte & Touche LLP as Independent Auditor
Stockholders ratified the appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. This move reaffirms the company’s commitment to robust financial reporting and oversight.
- Votes in Favor: 882,420,139
- Votes Against: 1,675,960
- Abstentions: 1,070,960
- Broker Non-Votes: None reported
Other Governance Disclosures
- Emerging Growth Company Status: ImmunityBio is not an emerging growth company as defined by the Securities Act of 1933 and the Securities Exchange Act of 1934.
- Soliciting Material, Written Communications, Tender Offers: The company did not file any written communications, soliciting material, or pre-commencement tender offer communications in connection with this 8-K.
Implications for Shareholders
- Leadership Stability: The re-election of the full board, especially key figure Dr. Patrick Soon-Shiong, signals continuity in strategic direction and management, potentially supporting investor confidence.
- Financial Transparency: The ratification of Deloitte & Touche LLP as independent auditor ensures ongoing adherence to high standards in financial oversight, which can be price-supportive if investors remain confident in reported results.
- High Quorum and Support: With approximately 85% of shares represented and overwhelming majority votes for all proposals, the results demonstrate strong engagement and backing from the shareholder base.
- No New Price-Sensitive Announcements: There were no other governance or business updates, such as M&A activity, changes in capital structure, or regulatory events, disclosed in this filing.
Conclusion: Is This News Price Sensitive?
The results of the 2026 Annual Meeting reinforce ImmunityBio’s leadership and financial governance. While these are positive for corporate stability and transparency, there were no new business developments or strategic announcements that would be immediately price-sensitive or likely to move the share price in the short term. The results may provide modest reassurance to investors about ongoing direction and oversight but do not introduce new catalysts.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should consult their own financial advisors before making any investment decisions. The information provided here is based solely on the official SEC filing and may not include other material events or developments occurring after the date of the meeting.
